In Burkitt's lymphoma, c-myc is consistently found to be transcriptionally activated and overexpressed. More than 80% of c-Myc reduced B-lymphomas exhibit inactivation of Arf/p53, which correlates with cancer cell invasiveness, resistance to anticancer agents, and poor prognosis. Targeting c-Myc might be an effective approach to control B-lymphomas, but this strategy has a potential risk because loss of c-Myc has a major negative impact on physiological function and viability of normal cells. C-Myc directly and positively regulates transcription of the Cdk4 gene, which phosphorylates Rb and related pocket-binding proteins, promoting G1 cell cycle progression. Our previous studies showed that elimination of Cdk4 minimally affects normal cell proliferation, but completely abrogates transformation of murine fibroblasts induced by Ras activation and c-Myc overexpression or Arf/p53 disruption. These data suggest that Cdk4 and/or closely related Cdk6 can be a superb therapeutic target for treatment of malignancies with overexpression of c-Myc and inactivation of Arf/p53, such as B-lymphoma. The long-term goal is to develop therapeutic strategies to target the cell cycle machinery, specifically in cancer or pre-cancer lesions of patients. We hypothesize that Cdk4/6 play an essential role in B-lymphoma, and that Cdk4/6 silencing can inhibit proliferation of B-lymphoma without detrimental effects on normal cell cycle progression and development.
The specific aims are: (1) Determine whether Cdk4/6 plays an essential role in tumorigenicity and development of B-lymphoma driven by c-Myc by examining the effect of Cdk4/6 suppression on the B-lymphoma; (2) Determine whether Cdk4/6-siRNAs can be used as therapeutic agents in the mouse models; (3) Dissect the molecular mechanism of interaction of Cdk4/6 and B-lymphoma. The presented program takes innovative approaches that should lead us to a better understanding of interaction between Cdk4/6 and B-lymphoma, and should provide new strategies for more effective therapy in B-lymphoma. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA113579-02
Application #
7368467
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Arya, Suresh
Project Start
2006-07-10
Project End
2010-05-31
Budget Start
2007-04-16
Budget End
2007-05-31
Support Year
2
Fiscal Year
2006
Total Cost
$158,148
Indirect Cost
Name
Ohio State University
Department
Pathology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lu, Yuanzhi; Wu, Yongsheng; Feng, Xiaoling et al. (2014) CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest 124:1672-84
Nasser, Mohd W; Qamri, Zahida; Deol, Yadwinder S et al. (2011) Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 6:e23901
Xiao, Y; Ye, Y; Zou, X et al. (2011) The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction. Oncogene 30:287-300
Zhang, Wei Wei; Zhang, Xiao Jie; Liu, Hui Xian et al. (2011) Cdk1 is required for the self-renewal of mouse embryonic stem cells. J Cell Biochem 112:942-8
Feng, Xiaoling; Wu, Zhaojia; Wu, Yongsheng et al. (2011) Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. Mol Cell Biol 31:3457-71
Jin, Yucui; Zou, Xianghong; Feng, Xiaoling (2010) 3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs 21:814-22
Wu, Yongsheng; Feng, Xiaoling; Jin, Yucui et al. (2010) A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation. Cancer Prev Res (Phila) 3:818-28